Ms. Amie Phinney reports

DEFENCE THERAPEUTICS ANNOUNCES CONVERTIBLE DEBENTURE INTEREST PAYMENT

Defence Therapeutics Inc. has made a convertible debenture interest payment in common shares of the company.

The company announces that, in accordance with the terms and conditions of convertible debentures dated Sept. 15, 2025, representing a principal amount of $2-million and bearing interest at a rate of 8 per cent per annum, the company issued 320,000 common shares in the share capital of the company to the holders of the debentures in satisfaction of $160,000 in accrued and unpaid interest. Such interest shares are subject to a statutory hold period of four months plus one day in accordance with applicable securities laws. For further details regarding the debentures, see the company's news release dated Sept. 15, 2025, a copy of which is available under the company's profile at SEDAR+.

The company is also providing the update on its sharing agreement dated March 6, 2026, with Sorbie Bornholm LP, previously described in the company's news releases of March 9 and Feb. 27, 2026. The company has received the third settlement in the amount of $190,670.42 as of the settlement date of Oct. 14, 2026, against 606,060 placement shares released to SBLP. As of today, 9,090,911 placement shares are held in escrow in connection with the sharing agreement, and there are 15 settlement payments remaining.

We seek Safe Harbor.